Manufacturing

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

Articles

Understanding of scale-up parameters and use of process analytical technology are important to meet demand for larger batch sizes.

Challenges in Clinical Manufacturing for Topical Drugs

The acquisition will bring four new GMP-compliant facilities to the PCI network in the United States, Germany, and Canada.

PCI Acquires Bellwyck to Expand its Clinical Trial Services

The fully integrated, pre-qualified, pre-installed aseptic filling facility can be shipped globally for drug development and the manufacturing of personalized medicines and clinical trial supplies.

Vanrx Partners and G-CON Launch New Turnkey Facility

Catalent’s FlexDirect service offers sponsors multiple delivery options from a single inventory.

Catalent Launches Direct-to-Patient Clinical Supply Services

The trial will test experimental stem-cell treatments against biologic therapies for severe forms of relapsing multiple sclerosis.

NIH Launches Clinical Trial that Compares Stem Cell Transplantation to Biologic Therapies for MS Treatment

Label management specialist, Prisym ID, announced that its clinical trial solution, PRISYM 360, has been chosen by CME to be part of a just in time clinical trials handling system for the Medicines Manufacturing Innovation Centre project.

Prisym ID’s Clinical Trial Solution Chosen for Medicines Manufacturing Innovation Centre Project

Sangamo Therapeutics has revealed that the United Kingdom’s Medicines Healthcare Products Regulatory Agency (MHRA) has authorized the first in-human clinical trial evaluating a chimeric antigen receptor regulatory T cell (CAR-Treg) therapy.

Sangamo Gains MHRA Authorization for Clinical Trial of CAR-Treg Therapy

The company will produce the anti-HER3 antibody drug HMBD-001for use within a clinical partnership between Cancer Research UK and Hummingbird Bioscience to test the agent in a Phase I trial.

BioInvent Enters into Production Agreement Expected to Generate $30 million

The new location was established to ensure uninterrupted support for clients’ trials in both the United Kingdom and Europe if the UK leaves the European Union on Oct. 31, 2019, especially in the event of a no-deal Brexit.

Yourway Opens New Slovakia Location to Secure Client Trials in Case of No-Deal Brexit

The Phase III clinical studies for the drug candidate, elenbecestat, were discontinued based on a recommendation by a data safety monitoring board.

Clinical Trial Materials